Psoriasis and Obesity Share Inflammatory Pathways, Highlighting Need for Integrated Care
Psoriasis and obesity share inflammatory pathways that may contribute to greater disease severity, reduced treatment response, and increased metabolic complications, according to a clinical review examining the bidirectional relationship between the 2 conditions.
The review highlighted chronic systemic inflammation as a central mechanism linking psoriasis and obesity, with tumor necrosis factor-α, IL-6, IL-17, and IL-23 contributing to their shared pathophysiology.
Obesity is an independent risk factor for psoriasis development and exacerbation, while psoriasis-related inflammation may contribute to metabolic dysregulation. Together, these processes can create an inflammatory cycle that complicates disease management.
Clinical evidence indicates that patients with psoriasis and obesity experience greater skin disease severity, reduced quality of life, and diminished responses to systemic therapies, particularly fixed-dose biologics.
The authors emphasized the dermatologist's role in identifying associated conditions through early screening for metabolic syndrome, liver disease, and psoriatic arthritis. Recognizing these comorbidities may help guide treatment decisions and support more comprehensive disease management.
Weight management was identified as an important component of psoriasis care. The review noted that “weight loss of 5% to 10% can improve cutaneous outcomes and restore therapeutic efficacy,” highlighting the potential benefits of addressing obesity alongside inflammatory skin disease.
Emerging metabolic treatments, including glucagon-like peptide-1 receptor agonists, may provide additional opportunities for managing patients with both conditions. These therapies were identified as promising because of their potential effects on systemic inflammation and psoriasis severity.
However, the review emphasized the importance of considering both dermatologic and metabolic health rather than treating either condition independently.
“An integrated treatment approach addressing both inflammatory skin disease and metabolic health is essential for optimal patient care,” the authors concluded.
Reference
Thomas LE, Ghanim D, Ghebrial M, et al. Psoriasis and obesity: a clinical review of the bidirectional link and management implications. Cutis. 2026;117(3):84-87. doi:10.12788/cutis.1355
